Skip to main content
. 2014 Feb 17;19(2):2061–2076. doi: 10.3390/molecules19022061

Figure 4.

Figure 4

(A) Antiproliferative action of doxorubicin against parental (□) and MDR (■) mouse lymphoma cells; (B) Antiproliferative actions of 3 (□), 4 (■) and 5 (♦) against MDR mouse lymphoma cells; and (C) Antiproliferative effects of the solanidine analogs (19 and 1118, 5 µM) combined with 0.1 µM doxorubicin.